QuantLogix ← BLSM scorecard
📅 BLSM Earnings Preview
BLSM
Next report (est.)
12/17/2026
Countdown
50 days
EPS growth YoY
+0.0%
Revenue growth YoY
+0.0%
Implied vs actual — last 2 reports
ReportOptions impliedActual moveMarket was
09/18/2026 ±8.8% -4.0% over-priced
09/18/2026 ±8.8% -4.0% over-priced
Across these reports, options implied an average ±8.8% move vs an actual average of 4.0% — the stock stayed inside the implied band 100% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $-8.75 $0 $-24M
Q2 FY2025 $-5.51 $0 $-13M
Analyst posture
Buy / Strong Buy
10
Hold
1
Sell
0
No recent analyst revisions
Live 5-factor engine read: Buy · 65/100 Full scorecard →
Get alerted before every BLSM report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on BLSM before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

BLSM (BLSM) reports in 50 days, with the next report estimated for 12/17/2026. Across the last 2 reports, options priced an average ±8.8% earnings move while the stock actually moved 4.0% on average — the market has systematically over-priced BLSM's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 0.0%. QuantLogix's live 5-factor engine currently reads BLSM as a buy at 65/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →